In-vitro evaluation of doxorubicin cytotoxicity and cellular uptake in the presence and absence of multidrug resistance modulators

Pharmacy and Pharmacology Communications

Volumn 5, Issue 8, 1999, Pages 511-517

  Krishna, Rajesh ^a   Mayer, Lawrence D ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; DEXNIGULDIPINE; DEXVERAPAMIL; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; N (3,4 DIMETHOXYPHENETHYL) N METHYL 2 (2 NAPHTHYL) 1,3 DITHIANE 2 PROPYLAMINE; QUINIDINE; TAMOXIFEN; VALSPODAR; VERAPAMIL;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG UPTAKE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA P 388; LYMPHATIC LEUKEMIA; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN FOLDING;

EID: 0032820871     PISSN: 14608081     EISSN: None     Source Type: Journal    
DOI: 10.1211/146080899128735261     Document Type: Article

References (29)

1. Alaoui-Jamali, M. A., Yin, M. B., Mazzoni, A., Bankusli, I., Rustum, Y. (1989) Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog, Ro11-2933. Cancer Chemother. Pharmacol. 25: 77-83
2. Alaoui-Jamali, M. A., Schecter, R. L., Rustum, Y. M., Centurioni, M. G., Lehnert, S., Batist, G. (1993) In-vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933. J. Pharmacol. Exp. Ther. 264: 1299-1304
3. Alley, M. C., Scudiero, D. A., Monks, A., Hursey, M. L., Czerwinski, M. J., Fine, D. L., Abbot, B. J., Mayo, J. G., Shoemaker, R. H., Boyd, M. R. (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48: 589-601
4. Bankusli, I., Yin, M. B., Mazzoni, A., Abdellah, A. J., Rustum, Y. M. (1989) Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP. Anticancer Res. 9: 567-574
5. Boote, D. J., Dennis, I. F., Twentyman, P. R., Osborne, R. J., Laburte, C., Hensel, S., Smyth, J. F., Brampton, M. H., Bleehen, N. M. (1996) Phase I study of etoposide with PSC-833 as a modulator of multidrug resistance in patients with cancer. J Clin. Oncol. 14: 610-618
6. de Jong, G., Gelmon, K., Bally, M. B., Goldie, J., Mayer, L. D. (1995) Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative. Anticancer Res. 15: 911-916
7. Fan, D., Beltran, P. J., O'Brien, C. A. (1994) Reversal of multidrug resistance. In: Kellen, J. A. (ed.) Reversal of Multidrug Resistance in Cancer. CRC Press, Boca Raton, pp 93-124
8. Gekeler, V., Ise, W., Boer, R., Beck, J., Sanders, K. H., Zimmermann, P., Ulrich, W. R. (1995) Modulation of MRP-associated multidrug resistance. Proc. Am. Ass. Cancer Res. 36: 343
9. Goldstein, L. J. (1995) Clinical reversal of drug resistance. Curr. Probl. Cancer 19: 65-124
10. Hofmann, J., Ueberall, F., Egle, A., Grunicke, H. (1991) B-859-35, a new drug with antitumor activity reverses multidrug resistance. Int. J. Cancer 47: 870-874
11. Hofmann, J., Gekeler, V., Ise, W., Noller, A., Mitterdorfer, J., Hofer, S., Utz, I., Gotwald, M., Boer, R., Glossmann, H., Grunicke, H. H. (1995) Mechanism of action of dexniguldipine-HCl (B8509-035), a potent modulator of MDR. Biochem. Pharmacol. 49: 603-609
12. Jiang, X. -R., Kelsey, S. M., Wu, Y. -L., Newland, A. C. (1995) Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporine D analogue, SDZ PSC 833. Br. J. Haematol. 90: 375-383
13. Keller, R. P., Altermatt, H. J., Nooter, K., Poschmann, G., Laissue, J. A., Bollinger, P., Hiestand, P. C. (1992) SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein mediated multidrug resistance of murine leukemia. Int. J. Cancer 50: 593-597
14. Krishna, R., Mayer, L. D. (1997) Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug resistant solid tumors. Cancer Res. 57: 5246-5253
15. Krishna, R., de Jong, G., Mayer, L. D. (1997) Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin. Anticancer Res. 17: 3329-3334
16. Ramu, A., Glaubiger, D., Fuks, Z. (1984a) Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res. 44: 4392-4395
17. Ramu, A., Spanier, R., Rahamimoff, H., Fuks, Z. (1984b) Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukemia cells. Br. J. Cancer 50: 501-507
18. Sarris, A. H., Younes, A., McLaughlin, P., Moore, D., Hagemeister, F., Swan, F., Rodriguez, M. A., Romaguera, J., North, L., Mansfield, P., Callendar, D., Mesina, O., Cabanillas, F. (1996) Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 14: 233-239
19. Sikic, B. I., Fisher, G. A., Lum, B. L., Brophy, N. A., Yahanda, A. M., Adler, K. M., Halsey, J. (1994) Clinical reversal of multidrug resistance. Cancer Treat. Res. 73: 149-165
20. Tsuruo, T., Iida, H., Tsukagoshi, S., Sakurai, Y. (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41: 1967-1972
21. Tsuruo, T., Iida, H., Tsukagoshi, S., Sakurai, Y. (1982a) Increased accumulation of vincristine and adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 42: 4730-4733
22. Tsuruo, T., Iida, H., Kitatani, Y., Yokota, K., Tsukagoshi, S., Sakurai, Y. (1982b) Enhancement of vincristine and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin. Biochem. Pharmacol. 31: 3138-3140
23. Tsuruo, T., Iida, H., Naganuma, K., Tsukagoshi, S., Sakurai, Y. (1983a) Promotion of verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug. Cancer Res. 43: 808-813
24. Tsuruo, T., Iida, H., Nojiri, M., Tsukagoshi, S., Sakurai, Y. (1983b) Potentiation by vincristine and adriamycin in human hematopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res. 43: 2267-2272
25. Tsuruo, T., Iida, H., Nojiri, M., Tsukagoshi, S., Sakurai, Y. (1983c) Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 43: 2905-2910
26. Tsuruo, T., Iida, H., Kitani, Y., Yokota, K., Tsukaggoshi, S., Sukurai, Y. (1984) Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res. 44: 4303-4307
27. Van de Vrie, W., Schellens, J. H., Loss, W. J., Kolker, H. J., Verway, J., Stoter, G., Durante, N. M., Eggermont, A. M. (1996) Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the cc531 rat colon carcinoma model. J. Can. Res. Clin. Oncol. 122: 403-408
28. Watanabe T., Tsuge H., Oh-hara T., Naito M., Tsuruo T. (1995) Comparative study on reversal efficacy of SDZ PSC 833, cyclosproin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol. 34: 235-241
29. Watanabe T., Naito M., Oh-hara T., Itoh Y., Cohen D., Tsuruo T. (1996) Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid tumor bearing mouse models. Jpn. J. Cancer Res. 87: 184-193